|
|
Volumn 6, Issue 6, 2010, Pages 885-891
|
|
Salirasib in the treatment of pancreatic cancer.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
DEOXYCYTIDINE;
DRUG DERIVATIVE;
FARNESOL;
FARNESYL TRANS TRANSFERASE;
FARNESYLTHIOSALICYLIC ACID;
GALECTIN;
GEMCITABINE;
PROTEIN KINASE INHIBITOR;
PROTEIN P21;
SALICYLIC ACID DERIVATIVE;
TUMOR PROTEIN;
ANIMAL;
CELL MEMBRANE;
DISEASE FREE SURVIVAL;
DRUG ANTAGONISM;
DRUG EFFECT;
DRUG SCREENING;
ENZYMOLOGY;
GENE EXPRESSION REGULATION;
HUMAN;
METABOLISM;
MIDDLE AGED;
MOUSE;
NEOPLASM;
NUDE MOUSE;
PANCREAS TUMOR;
PHASE 1 CLINICAL TRIAL;
PROTEIN BINDING;
REVIEW;
SIGNAL TRANSDUCTION;
ANIMALS;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CELL MEMBRANE;
CLINICAL TRIALS, PHASE I AS TOPIC;
DEOXYCYTIDINE;
DISEASE-FREE SURVIVAL;
DRUG SCREENING ASSAYS, ANTITUMOR;
FARNESOL;
FARNESYLTRANSTRANSFERASE;
GALECTINS;
GENE EXPRESSION REGULATION, NEOPLASTIC;
HUMANS;
MICE;
MICE, NUDE;
MIDDLE AGED;
NEOPLASM PROTEINS;
NEOPLASMS;
PANCREATIC NEOPLASMS;
PROTEIN BINDING;
PROTEIN KINASE INHIBITORS;
PROTO-ONCOGENE PROTEINS P21(RAS);
SALICYLIC ACIDS;
SIGNAL TRANSDUCTION;
MLCS;
MLOWN;
|
|
EID: 77957261391
PISSN: None
EISSN: 17448301
Source Type: Journal
DOI: 10.2217/fon.10.71 Document Type: Review |
|
Times cited : (45)
|
|
References (58)
|
